NUO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8 USD | 0.00% |
|
0.00% | +45.45% |
| Apr. 19 | Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 19 | Exor-backed NUO invests in Italian teenage clothing chain Subdued | RE |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 0.9489 | 2.847 | 13.62 | 0.003025 | 62.7 | 24.33 |
| Enterprise Value (EV) 1 | 0.621 | 3.305 | 13.46 | -1.412 | 60.98 | 23.66 |
| P/E ratio | -0.57 x | -2.38 x | 1.65 x | -0 x | -18.9 x | -7.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.69 x | 19.5 x | - | - | 559 x | 40 x |
| EV / Revenue | 0.45 x | 22.6 x | - | - | 543 x | 38.9 x |
| EV / EBITDA | -0.44 x | -3.76 x | -46.7 x | - | -18.4 x | -7.5 x |
| EV / FCF | -0.82 x | -14.6 x | -5,733 x | 16.4 x | -22.3 x | -12.8 x |
| FCF Yield | -122% | -6.86% | -0.02% | 6.11% | -4.49% | -7.82% |
| Price to Book | -11.6 x | -2.35 x | -23 x | 0 x | 28.6 x | 23.4 x |
| Nbr of stocks (in thousands) | 23,722 | 23,722 | 30,259 | 30,259 | 41,799 | 44,242 |
| Reference price 2 | 0.0400 | 0.1200 | 0.4500 | 0.000100 | 1.500 | 0.5500 |
| Announcement Date | 4/16/19 | 4/15/22 | 4/15/22 | 4/15/22 | 4/17/23 | 4/19/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.371 | 0.1462 | - | - | 0.1122 | 0.6085 |
| EBITDA 1 | -1.403 | -0.8793 | -0.2882 | - | -3.314 | -3.153 |
| EBIT 1 | -1.505 | -0.9692 | -0.3781 | -0.0907 | -3.321 | -3.168 |
| Operating Margin | -109.78% | -663.03% | - | - | -2,958.21% | -520.65% |
| Earnings before Tax (EBT) 1 | -1.542 | -1.195 | -0.0909 | -0.0907 | -3.172 | -3.171 |
| Net income 1 | -1.542 | -1.195 | -0.0909 | -0.0907 | -3.172 | -3.171 |
| Net margin | -112.49% | -817.43% | - | - | -2,825.6% | -521.17% |
| EPS 2 | -0.0700 | -0.0504 | 0.2734 | -0.0300 | -0.0793 | -0.0754 |
| Free Cash Flow 1 | -0.7564 | -0.2268 | -0.002347 | -0.0863 | -2.738 | -1.851 |
| FCF margin | -55.19% | -155.13% | - | - | -2,439.11% | -304.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/16/19 | 4/15/22 | 4/15/22 | 4/15/22 | 4/17/23 | 4/19/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.46 | - | - | - | - |
| Net Cash position 1 | 0.33 | - | 0.16 | 1.41 | 1.72 | 0.67 |
| Leverage (Debt/EBITDA) | - | -0.5217 x | - | - | - | - |
| Free Cash Flow 1 | -0.76 | -0.23 | -0 | -0.09 | -2.74 | -1.85 |
| ROE (net income / shareholders' equity) | -769% | 185% | 10.6% | -62.7% | -213% | -196% |
| ROA (Net income/ Total Assets) | -78.4% | -96.8% | -108% | -6.96% | -92% | -80.4% |
| Assets 1 | 1.967 | 1.235 | 0.0842 | 1.302 | 3.449 | 3.944 |
| Book Value Per Share 2 | -0 | -0.0500 | -0.0200 | 0.0200 | 0.0500 | 0.0200 |
| Cash Flow per Share 2 | 0.0300 | 0 | 0.0100 | 0.0400 | 0.0500 | 0.0200 |
| Capex | - | - | - | - | 0.06 | 0.01 |
| Capex / Sales | - | - | - | - | 53.44% | 1.19% |
| Announcement Date | 4/16/19 | 4/15/22 | 4/15/22 | 4/15/22 | 4/17/23 | 4/19/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +45.45% | 35.39M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
- Stock Market
- Equities
- AURX Stock
- Financials Nuo Therapeutics, Inc.
